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was 38.2 years (SD = 12.6) and 62.7% were female. 85.9% of our respondents were 
born outside Canada and 71.8% were ethnically from Asian areas. Effectiveness of 
the preventive treatment (Risk of developing active TB after treatment, −0.23, p < 
0.001), Risk of developing liver damage (−0.16, p < 0.001), Length of treatment 
(−0.05, p < 0.001), Risk of developing skin rash (−0.03, p = 0.002), and Risk of 
developing fatigue (−0.03, p = 0.009) were signiﬁcant determinants of respondents’ 
choices of preventive treatment. The negative preference estimates revealed that 
respondents were averse to higher risk of developing active TB, higher risk of develop-
ing liver damage, skin rash and fatigue, and longer period of treatment. Frequency of 
clinic visit was not a signiﬁcant factor. Respondents’ preferences varied according to 
their socio-demographic characteristics, past experiences of TB, BCG vaccination 
status, and the reason for tuberculin skin test. CONCLUSIONS: The results suggest 
that respondents were consistently in favor of LTBI preventive treatment with higher 
effectiveness, less side effects and shorter length.
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MINNESOTA NICOTINE WITHDRAWAL SCALE (MNWS) USING 
ABSTINENCE PROFILES IN TREATMENTS WITH VARENICLINE AND 
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OBJECTIVES: To conduct a post-hoc analysis of the time-courses of MNWS item or 
domain scores (MNWS scores) and weekly point prevalence of abstinence (PVR) 
during the treatment phase of a previously-published (Aubin et al, 2008) randomized 
open-label clinical trial of varenicline (N = 376) vs. NRT (N = 370). METHODS: 
Current cigarette smokers, motivated to quit smoking, participated in the trial and 
completed the MNWS instrument. Descriptive statistics (mean ± standard error) of 
the MNWS scores from weeks 2 to 7 were computed. Time-course comparisons strati-
ﬁed by PVR were performed, with weekly responders deﬁned by PVR = 0 and non-
responders otherwise. Multivariate repeated-measures mixed-effects regression was 
conducted for each MNWS domain score as the outcome variable. Covariates included 
baseline, treatment, patient characteristics, smoking history and PVR. Statistical sig-
niﬁcance was reached when two-sided p ≤ 0.05. RESULTS: The mean baseline MNWS 
scores of varenicline vs. NRT were comparable. By PVR, varenicline signiﬁcantly 
reduced the mean urge to smoke vs. NRT in weeks 2, 3, 4 and 5 (0.45 ± 0.10; 0.28 
± 0.09; 0.27 ± 0.10; 0.27 ± 0.09, respectively; all p < 0.01) among responders, and 
in weeks 2 to 6 (0.59 ± 0.13; 0.44 ± 0.14; 0.46 ± 0.16; 0.52 ± 0.18; 0.38 ± 0.17; all 
p < 0.03) among non-responders. The mean negative affect scores were signiﬁcantly 
lower in weeks 2 to 5 and 7 (0.31 ± 0.07; 0.20 ± 0.06; 0.18 ± 0.07; 0.23 ± 0.07; 0.13 
± 0.06; all p < 0.03) among responders and in week 2 (0.22 ± 0.11; p < 0.04) among 
non-responders. Additionally, restlessness was signiﬁcantly reduced in weeks 2 to 5 
(0.45 ± 0.10; 0.33 ± 0.09; 0.22 ± 0.09; 0.22 ± 0.08; all p < 0.02) among responders 
and in week 2 (0.42 ± 0.14; p < 0.003) among non-responders, and similarly the 
reduction of increased appetite (0.38 ± 0.18; p < 0.05) among nonresponders in week 
7. CONCLUSIONS: Overall, lower mean patient-reported MNWS scores associated 
with symptoms of tobacco withdrawal were observed for varenicline than for NRT, 
reaching statistical signiﬁcance, particularly among abstainers. Differences in the 
dynamics of treatment effects along with concomitant abstinence status warrant 
further bivariate analyses.
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NEED FOR IMPROVING ACCESS TO ESSENTIAL MEDICINES AND 
TREATMENT BEHAVIOUR TO BRONCHIAL ASTHMA A CHRONIC 
DISEASE
Kotwani A
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OBJECTIVES: It is expected that chronic diseases will account for 73% of deaths and 
60% of the global diseases by 2020. India is experiencing a fast health transition, in 
2005 chronic disease contributed to an estimated 53% of deaths and 44% of disabil-
ity-adjusted life years lost. Chronic diseases are a serious public health issue, particu-
larly because they require long-term therapy. Asthma, a major chronic disease, has 
become a cause of global concern in terms of its increasing prevalence, morbidity, and 
economic impact. Improving access to essential medicines and adherence to standard 
treatment guidelines can decrease the morbidity and mortality. The present scenario 
of access to essential medicines and treatment behaviour to asthma in India is inves-
tigated. METHODS: Recent studies conducted (2007–2009) on asthma management 
and adherence to therapy were analysed. Data on availability and price of two essential 
medicines for asthma, beclomethasone and salbutamol inhalers was collated from ﬁve 
medicine price studies conducted (2003–04) in ﬁve states of India, Haryana, Karna-
taka, Maharashtra, Rajasthan and Chennai (capital, Tamil Nadu state). RESULTS: 
Except for Rajasthan no inhalers were on state essential medicine list and were not 
available in any of the public facility; in Rajasthan these inhalers were available only 
in public facility of capital city. Results of the asthma management studies indicate 
poor knowledge regarding treatment of bronchial asthma by prescribers, pharmacists 
and by patients and asthma is not treated according to standard treatment guidelines. 
More than 80% patients and/or prescribers are treating acute episodes, rather than 
focusing on long-term asthma control. Ninety-two percent of patients alter the dose 
of inhaled corticosteroids after the acute attack. CONCLUSIONS: Since the incidence 
of chronic diseases are increasing rapidly in India, there is urgent need for improving 
access to essential medicines, treatment guidelines, policy making, patient & provider 
education, and resource allocation for chronic diseases, like bronchial asthma.
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DRUG UTILIZATION PATTERNS FOR PEDIATRIC ASTHMA IN 
AMBULATORY CARE SETTINGS
Yang M, Patel A, Aparasu RR
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OBJECTIVES: This study examined the asthma medications prescribing patterns 
among pediatric asthma visits in ambulatory care settings in the United States. 
METHODS: A retrospective cross-sectional analysis of National Ambulatory Medical 
Care Survey (NAMCS) and the outpatient data of the National Hospital Ambulatory 
Medical Care Survey (NHAMCS) of year 2006–2007 was conducted involving chil-
dren aged less than 18 years and diagnosed with asthma (ICD-9-CM 493.XX). The 
analyses focused on medications based on the guidelines of the National Asthma 
Education and Prevention Program (NAEPP). Descriptive statistics was used to 
examine the prescribing pattern. RESULTS: According to NAMCS and NHAMCS, 
there were18 million (0.87%) physician ofﬁce visits by children with asthma. Long 
Acting β2 Agonist was highly prescribed among (57.50%) ofﬁce visits, followed by 
Leukotrine Modiﬁers (29.91%) and Inhaled Corticosteroids (27.88%). Oral Cortico-
steroids and Short Acting β2 Agonist were prescribed in 15.99%, and 14.18% of 
ofﬁce visits, respectively. In terms of individual medicines, Albuterol, was mostly 
prescribed among 10.43 million visits, followed by Montelukast, 5.42 million visits. 
Prednisolone was prescribed in 2.71 million visits and Levalbuterol was prescribed in 
2.36 million visits. CONCLUSIONS: Long Acting β2 Agonist and Leukotrine Modi-
ﬁers was the most highly prescribed medication class and Albuterol and Montelukast 
were highly prescribed individual medications in pediatrics asthma ambulatory care 
visits in the United States.
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CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN 2006–2007
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OBJECTIVES: To examine the prescribing pattern of drugs for the treatment of 
Chronic Obstructive Pulmonary Disease (COPD) in ambulatory care visits and to 
assess the variation in the prescription of ﬁrst line of therapy across sex, race and 
geographic region. METHODS: Data of 2006–2007 National Ambulatory Medical 
Care Survey (NAMCS) and outpatient ﬁles of National Hospital Ambulatory Medical 
Care Survey (NHAMCS) were analyzed. Sample data was weighted to provide US 
national estimates. Adults more than 25 years of age were included in the study and 
COPD visits were identiﬁed (ICD-9-CM: 491,492,496). First line of therapy was 
deﬁned as prescription of either beta-agonist or anticholinergics. Descriptive weighted 
analysis was performed to examine the prescribing pattern of drugs and multivariate 
logistic regression using complex survey design was conducted to identify variation 
for ﬁrst line of therapy across sex, race and region, while controlling for age, tobacco 
use, insurance, metropolitan area, and region. RESULTS: In 2006–2007, COPD 
accounted for 70.25 million (95% CI: 60.69–79.81) ambulatory care visits by adult 
patients, representing 3.3% of the total ambulatory visits. Of these visits, majority 
were made by females (59.14%), whites (87.31%) and living in the southern region 
(44.78%). COPD medications were only prescribed in 42.13% of the visits. Highly 
prescribed medications were bronchodilators (34.33%), followed by combination 
therapy (9.66%) and inhaled corticosteroids (2.71%). First line of therapy was pre-
scribed at 25.17% (95% CI: 21.62–28.72) visits: 19.16% visits received beta-agonist 
and 11.84% visits received anticholinergics. No variation was found across sex, 
race, and region for the prescription of ﬁrst line of therapy for COPD. CONCLU-
SIONS: Bronchodilators were highly prescribed medication for COPD in outpatient 
visits. The ﬁrst line of therapy did not vary signiﬁcantly across sex, race and region 
for COPD.
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OBJECTIVES: To ﬁnd out demographic factors predicting inhaled corticosteroid 
utilization among asthma patients. METHODS: The study utilized data from the 
four-state sample of National Asthma Survey (NAS), sponsored by the National 
Center for Environmental Health (NCEH), Centers for Disease Control. The study 
population consisted of patients with persistent asthma as (deﬁned by the symptoms 
score based on NHLBI guidelines). Frequency distributions were made to characterize 
the study population. Logistic regression was carried out to determine the odds of 
reporting use of inhaled corticosteroids across various demographic variables (Age, 
gender, race, income level, insurance coverage, and disease severity). Data was ana-
lyzed using SAS v9.0. RESULTS: Underutilization of inhaled corticosteroids (ICSs) 
was found to exist in the asthmatic patients as over half of our study population 
(52.6%,n = 323)did not even report the use of ICSs. Disparities were also found to 
exist in our study across various variables. Blacks were found to have much lower 
odds of using ICSs when compared to other races (OR,0.572;CI,0.566–0.579). Black 
uninsured children also demonstrated similar trends. Patients having some form of 
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insurance coverage (OR, 1.768; CI,1.745–1.792)and those having higher income 
(OR,1.168;CI,1.155–1.182)were found to have higher odds of using inhaled cortico-
steroids when compared to uninsured and people from low income categories respec-
tively. Aside from these, disease severity also predicted the use of controller drug. 
Patients with increased severity had higher odds of using ICSs (OR, 1.552; CI, 
1.537–1.568). The ﬁndings held true even after adjusting for other demographic 
factors. CONCLUSIONS: Underuse of ICSs continues to be a problem in asthma 
patients. This not only makes the control of disease difﬁcult but shoots up the health-
care expenditure. The study was successful in ﬁnding out vulnerable populations that 
can be targeted for inhaled corticosteroids use. The importance of adherence to treat-
ment and inhaled corticosteroids use are issues that need to be addressed.
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OBJECTIVES: To assess the impact of REMS approval on prescription pattern for 
three oral drugs used to treat common chronic conditions. We assessed relative impact 
on prescription volume for REMS-approved drugs against relevant competitors not 
requiring REMS. We described these trends over the 2006–2009 period including the 
9/27/2007 implementation of the REMS initiative. METHODS: We paired two top 
prescribed drugs for the treatment of asthma (Advair/Singulair), diabetes (Actos/
Avandia) and insomnia (Ambien/Lunesta). Each pairing included a REMS-approved 
drug (Advair, Actos and Ambien). We focused on the months leading to and following 
REMS approvals. For each pairing, volume of total prescriptions (TRx), new prescrip-
tions (NRx) and prescription switches (SRx) were collected using the Verispan’s 
VONA database. Statistical analyses were performed using one-way ANOVA. 
RESULTS: There were no signiﬁcant changes (p < 0.05) in the volume of TRx, NRx 
and SRx for Advair or Actos prior to or following approval. However, Ambien TRx 
were signiﬁcantly higher during and after the last quarter of 2008 compared to previ-
ous months (p = .008) while SRx were lower (p = 0.04). This increase did not come 
to the expense of Lunesta whose prescription volume stayed constant over the time 
period considered. CONCLUSIONS: The fear that additional safety requirements 
could be detrimental to drug prescriptions was not conﬁrmed in our analyses. In fact, 
FDA requirement for REMS approval appeared to impact prescription volume favor-
ably for one of the drugs considered. One possible explanation is the potential for 
increased interactions with providers thus the ability to better position the drug clini-
cally. However, these trends were observed with less than a two-year period post-
approval and only for a handful of drugs and conditions. Additionally, the differential 
impact of various REMS components such as medical guide and communication plan 
should be further investigated.
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ADULTS WITH ALLERGIC RHINITIS: NATIONAL AMBULATORY  
CARE SURVEY RESULTS.
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OBJECTIVES: To examine recent anti-allergic drug utilization patterns in adult 
patients with allergic rhinitis using National Ambulatory Care Survey data. 
METHODS: Data for this study was obtained from the 2006 and 2007 National 
Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory 
Medical Care Survey (NHAMCS) public use data ﬁles. Visits with a primary diagnosis 
of allergic rhinitis in adults (age >18 years) were identiﬁed. Descriptive weighted 
statistics was used to examine utilization patterns of various anti-allergic medications. 
A multivariate survey logistic was conducted to determine demographic and geo-
graphic variations associated with anti-allergic medication use in patients with allergic 
rhinitis. RESULTS: Allergic rhinitis accounted for 18.6 million adult ambulatory care 
visits in the United States. The majority of the visits were made by females (61.6%), 
whites (84.8%), and involved specialists (59.9%). Anti-allergic medications were 
prescribed in 55.1% (95%CI 39.2% −71.0%) of the total diagnosed visits. Antihis-
tamines were the most commonly prescribed anti-allergic medication (37.4%) (95%CI 
32.4%-46.5%) followed by intranasal steroids (28.3%) (95%CI 23.2%-31.8%). 
Topical nasal antihistamines and decongestants (7.8%) (95%CI 2.7%-9.9%), leukot-
rienes (6.3%) (95%CI 5.2%-6.8%), corticosteroids (3.4%) (95%CI 1.3%-4.3%), and 
oral decongestants (1.52%) (95%CI 0.4%-2.1%) were the least prescribed anti-
allergic medications. The multivariate logistic regression revealed that geographic 
region of the ofﬁce visits was signiﬁcantly associated with medication use. Outpatient 
visits in the Midwest (Odds Ratio (OR) 5.16, 95%CI 1.50–17.67), South (OR 6.3, 
95%CI 2.03–19.5), and West (OR 9.16, 95%CI 2.39–35.11) regions were more likely 
to be prescribed anti-allergic medications compared to those in the Northeast region. 
CONCLUSIONS: Anti-allergic medications were prescribed in over half of adult 
allergic rhinitis visits in the U.S. The ﬁndings highlight geographical variations in 
anti-allergic medication use for allergic rhinitis. Comprehensive research is needed to 
understand the reasons for geographic variation in the medication use for allergic 
rhinitis.
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IMPACT OF THE UK PUBLIC SMOKING BAN ON THE PRESCRIBING OF 
SMOKING CESSATION THERAPY IN PRIMARY CARE–A THIN 
DATABASE STUDY
Blak BT, Hards M, Thompson M, Dattani H
CSD EPIC, London, UK
OBJECTIVES: Over-the-counter nicotine replacement purchases increased immedi-
ately after the public smoking ban introduction in Scotland. The study objective was 
to evaluate the impact of the smoking bans throughout the UK on smoking cessation 
prescriptions (SCPs) or related general practice contacts (GPCs) in primary care. 
METHODS: Monthly data on SCPs (nicotine replacement therapy, bupropion, vareni-
cline) and GPCs were obtained from The Health Improvement Network (THIN) 
database, which holds anonymised longitudinal UK primary care data, 24 months 
before and after the ban in England (January 7, 2007), Wales (February 4, 2007), 
Scotland (March 26, 2006) and Northern Ireland (NI) (April 30, 2007). The percent-
age of active patients with ≥1 SCP and the percentage of GPCs which were smoking 
cessation-related were evaluated. Mann-Whitney tests compared percentages before 
and after the ban. RESULTS: Within each country SCPs increased slightly after the 
smoking ban, for example during the total 48 months 431,675 SCPs were prescribed 
in England, with 48.7% prescribed before the ban and 51.3% after. The median 
percentage of patients with ≥1 SCP increased slightly after the ban—in England the 
median was 0.28% before and 0.31% after, with no evidence of a difference (p = 
0.18), in Wales 0.36% and 0.49% (p = 0.001) respectively, Scotland 0.36% and 
0.37% (p = 0.85), and NI 0.48% and 0.54% (p = 0.09). The median percentage of 
GPCs decreased slightly—in England it was 1.87% before and 1.57% after, Wales 
2.08% and 1.81% respectively, Scotland 2.70% and 1.64%, and NI 2.95% and 
2.34%. There was evidence of a difference (p < 0.0001) in each country. CONCLU-
SIONS: The ban did not seem to impact smoking cessation activity in primary care 
greatly. Even though only signiﬁcant for Wales, the slight increase in patients with 
SCPs may be owing to the ban. The decrease in smoking-related GPCs could be owing 
to patients being referred to or seeking support outside of primary care.
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INFECTIONS BY PRIMARY CARE PHYSICIANS IN NEW DELHI, INDIA
Kotwani A1, Roy Chaudhury R2, Holloway K3
1Vallabhbhai Patel Chest Institute, Univ of Delhi, Delhi, India, 2Indraprastha Apollo Hospitals, 
New Delhi, India, 3World Health Organisation, Geneva, Switzerland
OBJECTIVES: In the absence of community-based databases on antibiotic use in 
developing countries recently a methodology was established for surveillance of anti-
biotic use at New Delhi by conducting ‘Exit Interviews’ of the patients. This study 
was conducted to obtain information on current prescribing rates of antibiotics in 
acute respiratory illnesses (ARI), a condition where misuse of antibiotics is common. 
METHODS: Antibiotic use data was collected from public and private sector facilities 
from four municipal wards (residential localities) around a tertiary care hospital where 
the antibiotic resistance work was being conducted. For public sector, 8 dispensaries 
(primary health care) and 2 secondary care level facilities were enrolled. For private 
sector, 20 willing and cooperative general practitioners and specialists practising in 
the chosen areas were selected. Patients after consultation with prescriber were asked 
if they had cough/common cold/sore throat (symptoms of ARI). Patients with any of 
these symptoms were enrolled for exit interview and his/her prescription was moni-
tored. Antibiotic use data was collected per month over one year (December 
2007-November 2008).The percentage of patients receiving antibiotic and pattern of 
consumption for various antibiotics was analysed. RESULTS: At public facilities 
45.3% (746/1646) and at private facilities 56.7% (259/457) of patients with ARI were 
prescribed at least one antibiotic. In public sector, macrolides (29.3%), penicillins 
(26.3%), and cephalosporins (16.2%) and in private sector, cephalosporins (40%), 
ﬂuoroquinolones (21.7%), and penicillins (19.7%) were mainly prescribed. At public 
facilities, main members from macrolides were roxithromycin and erythromycin; for 
penicillins, amoxicillin and amoxicillin+clavulinic acid; for cephalosporins, cefuroxime 
and cephalexin were used. At private clinics, for cephalosporins, cefuroxime, cefpo-
doxime proxetil, ceﬁxime, ceﬁxime+clavulinic acid; for ﬂuoroquinolones, levoﬂoxacin 
and oﬂoxacin; and for penicillins group amoxicillin+clavulinic acid were prescribed. 
CONCLUSIONS: Over-prescription and irrational use of antibiotics was seen in ARI. 
In-depth behaviour study for prescribers and strategies to manage ARI are needed.
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INFECTIONS IN ADULT PRIMARY CARE: IS GOOD INSURANCE BAD 
FOR ANTIBIOTIC PRESCRIBING?
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OBJECTIVES: Substantial overuse of newer broad-spectrum antibiotics has been a 
grave public health concern as it results in drug resistance and substantial health care 
costs. Little is known about how health insurance status is related with the prescribing 
of antibiotics at the adult primary care. We aim to assess the relationship between 
broad-spectrum antibiotic prescribing and patients’ insurance status in treatment of 
acute respiratory tract infections (ARTI) in adult primary care using a nationally 
representative sample. METHODS: We analyzed 2006 National Ambulatory Medi-
care Care Survey, for adult aged 18 years or older cared for ARTI. Those patients 
with a concomitant diagnosis with other common outpatient infections that might be 
